Announcements
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Collegium Provides 2024 Financial Guidance
- Appeals Court Upholds PTAB’s Finding of Invalidity of Purdue’s 961 Patent
- Collegium Announces $25 Million Accelerated Share Repurchase Program
- Collegium to Participate in Upcoming Investor Conferences
More ▼
Key statistics
As of last trade Collegium Pharmaceutical Inc (354:DUS) traded at 35.00, -6.91% below its 52-week high of 37.60, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.60 |
---|---|
High | 35.00 |
Low | 34.60 |
Bid | 34.60 |
Offer | 35.40 |
Previous close | 34.80 |
Average volume | 0.00 |
---|---|
Shares outstanding | 32.71m |
Free float | 32.25m |
P/E (TTM) | 42.52 |
Market cap | 1.23bn USD |
EPS (TTM) | 0.8823 USD |
Data delayed at least 15 minutes, as of May 03 2024 15:30 BST.
More ▼